A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

NCT05661916 ↗

Phase 1 Completed 96 enrolled Alnylam Pharmaceuticals

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single ascending doses of ALN-TTRSC04.

Timeline

Start: 2023-01-16
Primary completion: 2025-09-30
Completion: 2025-09-30

Publications

Badri P, Kolachana K, Duong A, Lasko M, Nandi T, Mehrotra N, Robbie GJ. Platform Assessment of Concentration-QTc Relationship Across GalNAc-siRNA Molecules. Clin Pharmacokinet. 2026 Feb;65(2):293-311. doi: 10.1007/s40262-025-01606-0. Epub 2025 Dec 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALN-TTRSC04	Unknown	—	Subcutaneous

Indications

No indication recorded.